The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / California Rheumatology Alliance 2013 Meeting: Rheumatologists Advised to Drop Prednisone Maintenance Therapy in Lupus Patients

California Rheumatology Alliance 2013 Meeting: Rheumatologists Advised to Drop Prednisone Maintenance Therapy in Lupus Patients

July 1, 2013 • By Stephanie Cajigal

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Since most SLE flares are mild to moderate, she suggested treating them with a burst of steroids, with either a medrol dose pack or triamcinolone 100-mg intramuscular, rather than with maintenance prednisone, similar to how neurologists treat multiple-sclerosis flares with steroids and then nothing.

You Might Also Like
  • California Rheumatology Alliance 2013 Meeting: The Future of Rheumatoid Arthritis
  • California Rheumatology Alliance 2013 Meeting: Aim for Remission in Rheumatoid Arthritis
  • ACR 2013 State-of-the-Art Clinical Symposium: What’s Next in Therapy for Osteoarthritis, Rheumatoid Arthritis, and Lupus?
Explore This Issue
July 2013
Also By This Author
  • California Rheumatology Alliance 2013 Meeting: Aim for Remission in Rheumatoid Arthritis

Dr. Petri described the results of a clinical trial showing that patients experienced substantial improvement by days one and two after starting the therapy. By one month, the patients did not require rescue therapy. “Now if they had, we would have known they needed to start an immunosuppressant drug. If someone breaks through a burst of steroids, they’re telling you it’s not just a flare, they’re having some constant activity that needs to be suppressed,” she said, noting that triamcinolone injections should not be given more often than every three months.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Stephanie Cajigal is a medical journalist based in California.

References

  1. Thamer M, Hernán MA, Zhang Y, Cotter D, Petri M. Prednisone, lupus activity, and permanent organ damage. J Rheumatol. 2009;36:560-564.
  2. Magder LS, Petri M. Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus. Am J Epidem. 2012;176:708-719.

Pages: 1 2 3 | Single Page

Filed Under: Conditions, DMARDs & Immunosuppressives, Drug Updates, SLE (Lupus) Tagged With: HYDROXYCHLOROQUINE, Lupus, prednisone, SLE, TreatmentIssue: July 2013

You Might Also Like:
  • California Rheumatology Alliance 2013 Meeting: The Future of Rheumatoid Arthritis
  • California Rheumatology Alliance 2013 Meeting: Aim for Remission in Rheumatoid Arthritis
  • ACR 2013 State-of-the-Art Clinical Symposium: What’s Next in Therapy for Osteoarthritis, Rheumatoid Arthritis, and Lupus?
  • ACR/ARHP Annual Meeting 2012: New Research Delves Into the Risk of Comorbidities for Patients with Lupus

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)